06 March 2020 | GENEVA -- A Special Collection on Advances in Clinical Trial Design for Development of New Treatments for Tuberculosis has been released by PLOS Medicine. This Special Collection, that is now complete with the publication of its last paper, contains a series of articles that articulate the essential new steps in clinical research that will pave the way for the development of future optimal treatment for all forms of tuberculosis. The Collection has been sponsored by the World Health Organization (WHO) and the French National Research Institute for Sustainable Development (IRD-France), and coordinated by Dr Christian Lienhardt, Research Director at IRD-France and Dr Payam Nahid, Professor at University of California, San Francisco, USA

New articles were included in the Special Issue, released by PLOS Medicine in the beginning of April, focusing on new approaches to fighting and ending TB, including discovery and validation of novel biomarkers and diagnostic technologies, development of new treatments, testing of vaccines, and implementation studies of new strategies for diagnosis and treatment of TB.

This week, publication of a special issue on tuberculosis (TB) begins in PLOS Medicine, advised by guest editors Richard Chaisson of Johns Hopkins University, Claudia Denkinger of the University of Heidelberg, and Mark Hatherill of the South African Tuberculosis Vaccine Institute.

To commemorate World TB Day, a Special Collection has been released by PLOS Medicine containing a series of articles that articulate the essential new steps in clinical research that will pave the way for the development of tomorrow's optimal treatment for all forms of tuberculosis. This Special Collection is sponsored by the World Health Organization (WHO) and the French National Research Institute for Sustainable Development (IRD-France), and is co-ordinated by Dr Christian Lienhardt, Research Director at IRD-France and Dr Payam Nahid, Professor at University of California, San Francisco, USA.

The editors of PLOS Medicine together with guest editors Claudia Denkinger, Richard Chaisson, and Mark Hatherill announced a forthcoming Special Issue focused on new approaches to alleviate the individual and epidemiological burden of TB.

Several interventions for tuberculosis (TB) control have been recommended by the World Health Organization (WHO) over the past decade. These include isoniazid preventive therapy (IPT) for HIV-infected individuals and household contacts of infectious TB patients, diagnostic algorithms for rule-in or rule-out of smear-negative pulmonary TB, and programmatic treatment for multidrug-resistant TB. There is no systematically collected data on the type of evidence that is publicly available to guide the scale-up of these interventions in low- and middle-income countries. We investigated the availability of published evidence on their effectiveness, delivery, and cost-effectiveness that policy makers need for scaling-up these interventions at country level.